Protara Therapeutics
TARA
43 hedge funds and large institutions have $69.2M invested in Protara Therapeutics in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 4 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.81% less ownership
Funds ownership: 54.97% → 54.16% (-0.81%)
4% less funds holding
Funds holding: 45 → 43 (-2)
38% less capital inflows, than outflows
Capital inflows: $1.79M | Capital outflows: $2.89M
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$1.21M |
| 2 |
State Street
Boston,
Massachusetts
|
+$282K |
| 3 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$161K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$37.4K |
| 5 |
Citigroup
New York
|
+$29.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.86M |
| 2 |
Monashee Investment Management
Boston,
Massachusetts
|
-$508K |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$319K |
| 4 |
BlackRock Fund Advisors
San Francisco,
California
|
-$89.6K |
| 5 |
Morgan Stanley
New York
|
-$31.3K |
TARA Hedge Fund Activity: Q1 2016 in Review
43 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2016, worth a combined $69.2M — down 51% from $141M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TARA and 2 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 12 added.
The largest buyer was RA Capital Management, adding an estimated $1.21M. The largest seller was Fidelity Investments, cutting an estimated $1.86M.
- 43 institutional investors held Protara Therapeutics (TARA) as of Q1 2016, down from 45 in Q4 2015.
- Funds reported $69.2M of Protara Therapeutics stock for Q1 2016, down 51% quarter-over-quarter.
- 2 funds opened new Protara Therapeutics positions in Q1 2016 and 4 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q1 2016 was RA Capital Management, an estimated $1.21M added.
- The largest Protara Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $1.86M sold.
Based on aggregated 13F filings for Q1 2016.